Janssen Pharmaceutica NV Sustainability Profile
Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson, is a leading pharmaceutical company headquartered in Belgium (BE). Founded in 1953, Janssen has established itself as a key player in the global healthcare industry, focusing on innovative solutions across various therapeutic areas, including oncology, immunology, neuroscience, and infectious diseases. With a strong presence in Europe, North America, and Asia, Janssen is renowned for its commitment to research and development, delivering unique products that address unmet medical needs. Notable achievements include the development of groundbreaking treatments that have transformed patient care. Janssen's dedication to advancing healthcare through science and innovation solidifies its position as a trusted leader in the pharmaceutical sector.
DitchCarbon Score
How does Janssen Pharmaceutica NV's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Janssen Pharmaceutica NV's score of 81 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Janssen Pharmaceutica NV, headquartered in Belgium (BE), currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Johnson & Johnson, and as such, it inherits emissions data and climate commitments from its parent organisation. While no specific reduction targets or achievements are listed for Janssen Pharmaceutica NV, it follows the sustainability initiatives set forth by Johnson & Johnson. This includes commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded down from Johnson & Johnson. These initiatives aim to significantly reduce greenhouse gas emissions across various scopes, including Scope 1, 2, and 3 emissions. As part of its corporate family, Janssen Pharmaceutica NV aligns with Johnson & Johnson's broader climate strategies, which focus on achieving net-zero emissions and enhancing sustainability practices across its operations. However, specific metrics or targets for Janssen Pharmaceutica NV are not detailed in the available data.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Janssen Pharmaceutica NV's Industry?
How Carbon Intensive is Janssen Pharmaceutica NV's Location?
Janssen Pharmaceutica NV's Scope 3 Categories Breakdown
Janssen Pharmaceutica NV's Scope 3 emissions, which decreased by 2% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 72% of Scope 3 emissions.
Top Scope 3 Categories
Janssen Pharmaceutica NV's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Janssen Pharmaceutica NV has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
